{"name":"Syngene International","slug":"syngene","ticker":"SYNGENE.NS","exchange":"NSE","domain":"syngeneintl.com","description":"Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.","hq":"Bengaluru, India","founded":1995,"employees":"6533","ceo":"Jonathan Hunt","sector":"CRO / CDMO / Contract Research","stockPrice":399.05,"stockChange":8.15,"stockChangePercent":2.08,"marketCap":"$160.4B","metrics":{"revenue":37202001920,"revenueGrowth":-2.8,"grossMargin":68.3,"rdSpend":0,"netIncome":3520999936,"cash":10910999552,"dividendYield":0.32,"peRatio":45.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lynparza patent cliff ($1.4B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"deal","headline":"Syngene International wins contract from global pharma company","summary":"Syngene International has won a contract from a global pharmaceutical company to provide discovery and development services for a new drug candidate.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"earnings","headline":"Syngene International reports 20% increase in Q2 revenue","summary":"Syngene International has reported a 20% increase in revenue for the second quarter of 2023, driven by strong demand for its services.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNLThLSm81SjVZNXg3QzJYcHoyU1RZNkN6VEdCdjhPd214cm5CN0xNVmt4elRyemczM2ZCQnUwTXRiUHNUWkNWNWdkRWE3cVBCMFl1TlpXcDdzUk1TaEk1T3NLQjlzR1llOHdnNEhSODBHUVhBNUJqamtuUHRWT2JtZ0VlOXhIOG1XbEdSN2tyd0ZPLThYZzluaHA0cFZVOTA?oc=5","date":"2026-04-02","type":"trial","source":"Yahoo Finance UK","summary":"Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - Yahoo Finance UK","headline":"Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFA3cTVsei02cDVyLXJxZlV4eXdId043c0YtUWpGYkEyVVNqTi1HNTRnczlCNkVhWXFQbmlFWU03VEkzNG1JYzVZYXJXa3FwcWlfd2tEVEQ5YTR1QkZtblBqU2Q5TFFDUWlQaUxkUkc0anJxX2FZX2V6ag?oc=5","date":"2025-11-25","type":"pipeline","source":"Quiver Quantitative","summary":"Xtrackers Nifty 500 India ETF Holdings - Quiver Quantitative","headline":"Xtrackers Nifty 500 India ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE82X0JMTVZkOUhDVWJYa0dvYnlGVnc1bkxQbERJbkRlUzF2YWx1SlBzMDVsQjFZREdGZVBYbzI4SlJtN1JfdURyaEpWdlB6bjZsNVFVRGJUMnNpUjlZelE?oc=5","date":"2022-05-02","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Laurus Labs Limited (LAURUSLABS.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Laurus Labs Limited (LAURUSLABS.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOczJtVGVyN1FBOUJrU3lHT29ydmYzU2J5Tmlnak1FZXdlYkVvUGQ2d05KOUdjNFJTNTlnX01DVlFmbVNlenFvTVZFTDNGRG1mQjBaZEoxSHZCT1BSUzZRS19xakJscjhpVnBpTWlFZGtEYXhsVElHRktrREJoaWtoVDRfaGhzRGJQU1IxaVpldS1vTDk4Nmc5emZhSEVpYW1sZm9acnlOV0ZtdE9RR0FVMVlUZk8xdmhGa3c?oc=5","date":"2021-04-28","type":"pipeline","source":"Reuters","summary":"Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges - Reuters","headline":"Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE13Y2Q0bXdqQXdrTXZuUlZEbWVkZTlfdjV2SlY0dkJGaURISDZGakUtYzFxakhDWEJNTUVkOE1WaFNRNTJvSVoydS16TDJ5cWRUWHNCSDZFZUF1ZjRHTEE?oc=5","date":"2018-07-18","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Neuland Laboratories Limited (NEULANDLAB.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Neuland Laboratories Limited (NEULANDLAB.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermax","Laurus Labs","Aurobindo Pharma"],"therapeuticFocus":["Oncology","Infectious Diseases","Rare Diseases"],"financials":null,"yahoo":{"currentPrice":399.05,"previousClose":390.9,"fiftyTwoWeekHigh":754.85,"fiftyTwoWeekLow":380,"fiftyTwoWeekRange":"380.0 - 754.85","fiftyDayAverage":428.97,"twoHundredDayAverage":592.78,"beta":-0.16,"enterpriseValue":137917202432,"forwardPE":34.9,"priceToBook":3.39,"priceToSales":4.31,"enterpriseToRevenue":3.71,"enterpriseToEbitda":14.81,"pegRatio":0,"ebitda":9311250432,"ebitdaMargin":25,"freeCashflow":0,"operatingCashflow":0,"totalDebt":5816000000,"debtToEquity":12.3,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":618.75,"targetHighPrice":835,"targetLowPrice":480,"dividendRate":1.25,"payoutRatio":0.14,"fiveYearAvgDividendYield":0,"exDividendDate":1750982400,"insiderHeldPercent":53.1,"institutionHeldPercent":37,"sharesOutstanding":401751784,"floatShares":159124390,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":8.75,"epsForward":11.43,"revenuePerShare":91.74,"bookValue":117.84,"officers":[{"age":68,"name":"Mr. Peter James Jonathan Bains","title":"CEO, MD & Director"},{"age":null,"name":"Mr. Deepak  Jain","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Gaurav  Kushwaha","title":"Chief Technology Officer"},{"age":null,"name":"Dr. Jayashree  Aiyar Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. G.  Krishnan","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Chethan  Yogesh","title":"Company Secretary & Compliance Officer"},{"age":50,"name":"Mr. Surender Kumar Sharma","title":"General Counsel"},{"age":null,"name":"Mr. Sandeep  Nair","title":"Head of Corporate Communications"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.syngeneintl.com","phone":"91 80 6891 8000"}}